Immunologic Factor
Docs Embrace Takeda’s Eohilia, Creating Competition for Sanofi, Regeneron’s Blockbuster Dupixent
Takeda, Eohilia, Dupixent, Sanofi, Regeneron, Chronic Inflammatory Disease, Eosinophilic Esophagitis
BioMarin’s Brineura Receives Significant Label Expansion from FDA for Children Under 3 with CLN2 Disease
BioMarin, Brineura, FDA, Label Expansion, CLN2 Disease, Children Under 3, Cerliponase Alfa, Intraventricular Injection, Motor Ability Deterioration, Neurodegenerative Symptoms
Sanofi’s Dupixent Sales Surpass €3 Billion for the First Time
Sanofi, Dupixent, quarterly sales, record high, asthma medicine, earnings forecast
FDA Requests Additional Study on AstraZeneca’s Imfinzi for Lung Cancer Treatment
FDA, AstraZeneca, Imfinzi, Lung Cancer, Surgery, Adcomm
Merck’s Investigational RSV Antibody, Clesrovimab, Meets Primary Safety and Efficacy Endpoints in Phase 2b/3 Trial for Infant Prevention
Merck, RSV, Clesrovimab, Monoclonal Antibody, Infant Prevention, Respiratory Syncytial Virus, Phase 2b/3 Trial
AVEO Oncology’s Fotivda Combo Fails to Meet Primary Endpoint in Phase III Renal Cell Carcinoma Study
AVEO Oncology, Fotivda, tivozanib, renal cell carcinoma, Phase III clinical trial, TiNivo-2 study, nivolumab, Opdivo, kidney cancer
FDA Discourages Accelerated Approval for Agenus’ Colorectal Cancer Combination, Prompting Partnership Search
Agenus, FDA, Accelerated Approval, Colorectal Cancer, Botensilimab, Balstilimab, Immunotherapy Combination, Phase III Trial, Partnership
Almirall’s Ebglyss Gains NICE Recommendation for Atopic Dermatitis Treatment
Ebglyss, lebrikizumab, atopic dermatitis, NICE recommendation, Almirall, NHS England, biological therapy, moderate to severe atopic dermatitis
Pfizer’s R&D Chief Mikael Dolsten to Step Down After 15 Years of Leadership
Pfizer, Mikael Dolsten, Chief Scientific Officer, Research and Development, COVID-19 Vaccine, Successor Search
HilleVax Discontinues Norovirus Vaccine for Infants After Mid-Stage Trial Failure
HilleVax, norovirus vaccine, infants, mid-stage trial, failure, discontinuation